A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery

Trial Profile

A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Enoxaparin sodium
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms PRONOMOS
  • Most Recent Events

    • 17 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
    • 17 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.
    • 01 Apr 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top